Understanding the role of new systemic agents in the treatment of prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Understanding the role of new systemic agents in the treatment of prostate cancer

Published:2016-10 Issue: Volume:118 Page:8-13
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Corfield Julia¹^ORCID,Crozier Jack¹,Joshua Anthony M²,Bolton Damien M.¹,Lawrentschuk Nathan¹³⁴^ORCID

Affiliation:

1. Department of Surgery; Austin Hospital; University of Melbourne; Melbourne Australia

2. St Vincents Hospital; Sydney Australia

3. Olivia Newton-John Cancer Research Institute; Austin Hospital; Melbourne Australia

4. Department of Surgical Oncology; Peter MacCallum Cancer Centre; Melbourne Australia

Funder

Young urology researchers organisation

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.13633/fullpdf

Reference25 articles.

1. Effect of orchiectomy and irradiation on cancer of the prostate;Huggins;Ann Surg,1942

2. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346);Tangen;J Urol,2012

3. An update on enzalutamide in the treatment of prostate cancer;Merseburger;Ther Adv Urol,2015

4. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period;Wu;Cancer,2014

5. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?;Anticancer Research;2021-09-30

2. Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors;Advances in Therapy;2021-07-19

3. T7-Functionalized Cationic Peptide as a Nanovehicle for Co-delivering Paclitaxel and siR-MeCP2 to Target Androgen-Dependent and Androgen Independent Prostate Cancer;ACS Applied Bio Materials;2020-12-29

4. Prostate cancer in Asia: design of a patient registry to inform real-world treatments, outcomes, and quality of life;Prostate International;2019-09

5. Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy;Journal of Nuclear Medicine;2019-01-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3